Nicox
Valbonne, France · Health and Medical
Source
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
May 2026
Work here? Claim this profile
Overview
Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.
We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.
Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.
We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.
Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.
Contact Details
communications@nicox.com
Valbonne, France, Drakkar 2 - Bât D
+2
Founded
1996
Company Type
Public Limited Company
Employees
30-50
Categories
Keywords
#pharmaceuticals
#ophthalmology
#research and development
Listings
Products
Companies teams usually look at after Nicox
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.